Parvovirus B19 in Pregnancy

Akoijam Mamata Devi*
*Associate Professor, Shree Guru Gobind Singh Tricentenary University, Gurgaon, Haryana, India.
Periodicity:November - January'2016
DOI : https://doi.org/10.26634/jnur.5.4.4810

Abstract

Parvovirus B19 causes prolonged epidemics of erythema infectiosum. Infection causes clinically significant anemia in individuals with high red cell turnover, including the fetus. Transmission can occur via the respiratory route, hand-tomouth contact, blood products, and vertically from mother to the fetus. The virus replicates in rapidly proliferating cells, such as erythroblast precursors. In healthy hosts, the virus can cause a range of clinical manifestations, including erythema infectiosum (ie, fifth disease), transient aplastic crisis, chronic red cell aplasia, myocarditis, arthropathy, and nonimmune hydrops fetalis. Approximately 40% women of childbearing age are susceptible, and annual seroconversion rates vary from 1.5% during endemic periods to 10-15% during epidemics. Infection occurs in around 50% of susceptible women exposed at home and 20-30% following occupational exposure (for example, at a primary school). Maternal infection in the first half of pregnancy is associated with a 10% excess fetal loss and hydrops fetalis in 3% of cases (of which up to 60% resolve spontaneously or with appropriate management). No congenital abnormalities or long-term sequelae have been attributed to parvovirus B19 infection. The overall risk of serious adverse outcome of occupational exposure to parvovirus B19 infection during pregnancy is low (excess early fetal loss in 2-6/1,000 pregnancies and fetal death from hydrops in 2-5/10,000 pregnancies). It is not recommended that, susceptible pregnant women be excluded routinely from working with children during epidemics.

Keywords

Keywords: Erythema Infectiosum, Seroconversion, Childbearing, Epidemics, Occupational Exposure.

How to Cite this Article?

Devi, A.K. (2016). Parvovirus B19 in Pregnancy. i-manager’s Journal on Nursing, 5(4), 1-5. https://doi.org/10.26634/jnur.5.4.4810

References

[1]. Feldman DM, Timms D, Borgida AF, (2010). “Toxoplasmosis, parvovirus, and cytomegalovirus in pregnancy”. Clin Lab Med. Vol.30, No.3, pp.709-20.
[2]. Elsa Giorgio et al. (2010). “Parvovirus B19 During Pregnancy: a review”. J Prenat Med, Vol.4, No.4, pp.63-66.
[3]. Cossart YE, Field AM, Cant B, et al. (1975). “Parvoviruslike particles in human sera”. Lancet, Vol.1, pp.72-3.
[4]. Anderson MJ, Jones SE, Fisher-Jock SP, et al. (1983). “Human parvovirus, the cause of erythema infectiosum (Fifth disease)?”. Lancet, Vol.1, pp.1378.
[5]. Lamont RF, Sobel JD, Vaisbuch E, et al., (2010). “Parvovirus B19 infection in human pregnancy”. BJOG. Vol.118, No.2, pp.175-86.
[6]. Health Protection Agency, (2012). “Increased parvovirus B19 activity in England and Wales”. Health Protection Report, Vol.6, No.24.
[7]. Stelma FF, Smismans A, Goossens VJ, et al., (2008). “Occupational risk of human Cytomegalo virus and Parvovirus B19 infection in a female day care personnel in the Netherlands; a study based on seroprevalence”. Eur J Clin Microbiol Infect Dis, Vol.28, No.4, pp.393-7.
[8]. De Jong EP, Walther FJ, Kroes AC, et al., (2011). “Parvovirus B19 infection in pregnancy: new insights and management”. Prenat Diagn. Vol.31, No.5, pp.419-25. doi: 10.1002/pd.2714. Epub 2011 Feb 24.
[9]. Tolfvenstam T, and Broliden K. (2009). “Parvovirus B19 infection”. Semin Fetal Neonatal Med, Vol.14, No.4, pp.218-21.
[10]. Ergaz Z, and Ornoy A. (2006). “Parvovirus B19 in pregnancy”. Reprod Toxicol, Vol.21, No.4, pp.421–35.
[11]. De Haan TR, de Jong EP, Oepkes D, Vandenbussche FP, Kroes AC, and Walther FJ. (2008). “Infection with human parvovirus B19 (fifth disease') during pregnancy: potential life-threatening implications for the foetus”. Ned Tijdschr Geneeskd. Vol.152, No.21, pp.1185-90.
[12]. Crane J. (2002). “Parvovirus B19 infection in pregnancy”. J Obstet Gynaecol Can. Vol.24, No.9, pp.727- 743.
[13]. Roberts AB, Mitchell JM, Lake Y, Pattison NS. (2001). “Ultrasonographic surveillance in red blood cell alloimmunization”. Am J Obstet Gynecol, Vol.184, pp.1251-5. [PubMed]
[14]. Mari G. (2001). “Non invasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization”. N Engl J Med. Vol.342, pp.9-14.
[15]. GL Gilbert, (2000). Parvovirus B19 infection and its significance in pregnancy, in Communicable Diseases Intelligence.
[16]. Johnson DR, Fisher RA, Helwick JJ, Murray DL, Patterson MJ, Downes FP. (1994). “Screening maternal serum alpha-fetoprotein levels and human parvovirus antibodies”. Prenat Diag. Vol.14, pp.455-8.
[17]. Health Protection Agency (2011). Guidance on Viral Rash in Pregnancy.
[18]. Parvovirus B19 infection, (2010). NICE CKS.
[19]. Divakaran TG, Waugh J, Clark TJ, Khan KS, Whittle MJ, and Kilby MD. (2001). “Non invasive techniques to detect fetal anemia due to red blood cell alloimmunization: a systematic review”. Obstet Gynecol, Vol.98, pp.509-17.
[20]. Rodis JF, Hovick TJ, Jr, Quinn DL, Rosengren SS, and Tattersall P. (1988). “Human parvovirus infection in pregnancy”. Obstet Gynecol, Vol.72, pp.733-8.
[21]. Morita E, Nakashima A, Asao H, Sato H, and Sugamura K. (2003). “Human parvovirus B19 non structural protein (NS1) induces cell cycle arrest at G(1) phase”. J Virol, Vol.77, No.5, pp.2915-21.
If you have access to this article please login to view the article or kindly login to purchase the article

Purchase Instant Access

Single Article

North Americas,UK,
Middle East,Europe
India Rest of world
USD EUR INR USD-ROW
Pdf 35 35 200 20
Online 35 35 200 15
Pdf & Online 35 35 400 25

Options for accessing this content:
  • If you would like institutional access to this content, please recommend the title to your librarian.
    Library Recommendation Form
  • If you already have i-manager's user account: Login above and proceed to purchase the article.
  • New Users: Please register, then proceed to purchase the article.